09/05/2026
During the evaluation process, Dr. Jamie Justice, Executive Vice President of Health at XPRIZE and an adjunct professor of gerontology and geriatric medicine at Wake Forest University School of Medicine, noted something: that AgelessRx is one of the only approaches in the competition that looks like it could roll out to just about anyone, anywhere. Coming from someone who has spent her career studying the biology of aging and now oversees the entire XPRIZE Healthspan effort, that observation means something.
In a field that includes gene therapies, monoclonal antibodies, and some of the most cutting-edge targeted interventions in existence, that's a real distinction. Longevity science has a reach problem. The most exciting interventions being developed today are, in many cases, years away from broad accessibility, and some may never be. What we have built at AgelessRx is a clinician-guided, telehealth-delivered approach to drug repurposing that is already treating real patients, at scale, right now. The judges saw that not as a limitation compared to more targeted therapies, but as a distinct and meaningful advantage worth fighting for.
The goal has always been to make science-backed longevity care accessible to people who would never otherwise have it, not just those who can afford cutting-edge treatments or live near specialized clinics. If the data shows an effect, and we believe it will, the infrastructure to deliver it broadly already exists.
(For educational purposes only)